Abstract: A dental machine tool includes a first dental machining unit with a first housing and a first machining head. The first housing accommodates a first machining space. The first machining head is arranged in the first machining space and a first machining zone is allocated to the first machining head. A second dental machining unit has a second housing and a second machining head. The second housing accommodates a second machining space. The second machining head is arranged in the second machining space. A second machining zone is allocated to the second machining head. A movable dental object carrier is constructed to receive a dental object and to move the dental object linearly along an X-axis. The movable dental object carrier extends over the first machining zone, the second machining zone and an intermediate zone between the first and second machining zones.

Abstract: The present invention relates to a mechanized and automated process for producing a molded product, and to a molded product produced by said process.

Abstract: The invention relates to a pharmaceutical patch comprising a Lidocaine constituent and a Diclofenac constituent, wherein the relative weight content ratio of the Lidocaine constituent to the Diclofenac constituent is within the range of from about 7:1 to about 4:1, based on the equivalent weight of the non-salt form of Lidocaine and of Diclofenac, for use in the local treatment or prevention of pain, wherein the pain is neuropathic pain or wherein the pain has a neuropathic pain component. The pharmaceutical composition is suitable for topical administration and local pharmacological action via delivery of Lidocaine and Diclofenac into the skin and possibly also through and to other deeper tissues such as the synovial fluid without significant systemic exposure.

Abstract: The invention relates to a pharmaceutical patch comprising a Lidocaine constituent and a Diclofenac constituent, wherein the relative weight content ratio of the Lidocaine constituent to the Diclofenac constituent is within the range of from about 7:1 to about 4:1, based on the equivalent weight of the non-salt form of Lidocaine and of Diclofenac, for use in the local treatment or prevention of pain. The pharmaceutical composition is suitable for topical administration and local pharmacological action via delivery of Lidocaine and Diclofenac into the skin and possibly also through and to other deeper tissues such as the synovial fluid without significant systemic exposure.